One of the most important advancements in medicine is coming soon...


Plasmology4® is harnessing the 4th state of matter to improve the quality of patients' lives worldwide. The Company has developed a platform technology known as Plaz4® which has several potential applications in the healthcare market. Plasmology4® is currently advancing its Plaz4® technology for the treatment of multidrug-resistant bacteria, such as MRSA, in wounds and infections.


Plasmology4® is pioneering a new and innovative field called Plasma Medicine, which is the coalescence of plasma physics, life sciences, and clinical medicine to facilitate the use of "cold plasma" technology for healthcare applications. The Company has developed a novel medical device that kills bacteria in wounds, including multidrug-resistant bacteria, on contact. Plasmas, or ionized gasses, are referred to as the 4th state of matter – hence the brand name Plaz4®. By combining high voltage electricity with a non-combustible gas, a glowing gas plasma is generated and delivered to wound tissues where it destroys pathogens. While highly energized, Plaz4® is completely cool to the touch and will not heat up tissues. Plaz4® has demonstrated the ability to destroy a broad spectrum of pathogens in a variety of pre–clinical studies. Moreover, the potential impact of the technology to improve patient outcomes was recently recognized by the Food and Drug Administration when Plaz4® technology was granted a designation into the Breakthrough Devices Program [Press Release].

Plasmology4® has created a strong and valuable patent portfolio with 38 issued United States and International patents, several patents pending, and dozens of additional concepts under development. The Company's executive management team and Scientific Advisory Board are seasoned professionals and Key Opinion Leaders in the areas of biomedical device product development, intellectual property protection, plasma science and engineering, biomedical research, and healthcare systems and delivery.

Plasmology4 was awarded a federal grant under the Therapeutic Discovery Project Program. This program provided grants to small companies with a promising and important therapeutic technology. The Company was also nominated by the Arizona Technology Council as one of the Best Innovative Startup Companies in Arizona.

*Plaz4® Technology is under review by the FDA and is not currently approved for use in humans.

+ Plaz4® has demonstrated antimicrobial efficacy in laboratory tests against:

  • Gram positive (+) bacteria
  • Gram negative (-) bacteria
  • Multidrug-resistant (MDR) bacteria
    • A. baumannii - a clinical isolate from US military personnel
    • Methicillin resistant Staphylococcus aureus (MRSA) - classified as a serious threat by Centers for Disease Control and Prevention.
    • Methicillin and Gentamycin resistant Staphylococcus aureus
  • Most common hospital and community acquired wound infection bacteria including
    • Pseudomonas aeruginosa
    • Klebsiella pneumoniae
    • Escherichia coli
  • Candida albicans – a common fungal wound pathogen


Chief Executive Officer
Robert Hummel
David Jacofsky, MD
Chief Technology Officer
Greg Watson
Chief Scientific Officer
Marc Jacofsky, PhD
Director of Research
Emilia Kulaga, PhD


David Jacofsky, MD
Robert Hummel
James Ron Lawson
Ron Robinson, DC
Greg Watson
Stephen A. Brigido, DPM
Andrew W. Miller, Jr.
Kevin McDowell


David Jacofsky, MD, Chairman
Steve Moran, MD
Roy Sanders, MD
Marc Jacofsky, PhD
Robert Hummel